• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

David Michelson - Articles and news items

Merck logo

Merck advances development program for investigational Alzheimer’s Disease Therapy, MK-8931

Industry news / 10 December 2013 / Merck

The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months…

Merck logo

Merck provides update on Phase III clinical program for preladenant

Industry news, News / 23 May 2013 / Merck

Merck provides update on Phase III clinical program for preladenant, the company’s investigational parkinson’s disease medicine…

Merck logo

FDA approves ZIOPTAN™ (tafluprost ophthalmic solution)

Industry news, News / 13 February 2012 / Merck

ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +